{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-022236","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.588139+00:00","generated_at":"2026-06-15T01:24:53.585568+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health Q1 2023 revenue down 12% to $376K; gross profit up 61% to $113K","bullets":["Net loss $2.1M vs $2.2M prior year; cash $5.2M at quarter end.","Gross margin improved 61% on 17% higher ASP and 15% lower variable cost.","Revenue decline of 12% due to 27% unit sales drop and termination of less profitable retail channels.","Innovation pipeline expanded: vagus nerve stimulation program; collaboration with Feinstein Institute.","Closed $5M financing in Feb 2023; B2B sales portal and price increases implemented in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-022236","json":"https://secwatch.observer/filing/0000950170-23-022236.json","markdown":"https://secwatch.observer/filing/0000950170-23-022236.md","text":"https://secwatch.observer/filing/0000950170-23-022236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/0000950170-23-022236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/tivc-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:24:53.585568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9113cb464577599fa79874d4d80cac0b7b5e58c9","claim":"Valion Bio, Inc. reported the first quarter 2023 ended March 31, 2023 results: revenue $376 thousand, net income Net loss of $2.1 million.","evidence_excerpt":"First Quarter 2023 Financial Summary • Gross profit increased 61.3% to $113 thousand in the first quarter 2023, compared with $70 thousand in first quarter 2022, on a decrease of 12% in total revenue to $376 thousand in the first quarter 2023 from $428 thousand in first quarter 2022. • Net loss of $2.1 million in the first quarter 2023, compared with $2.2 million in first quarter 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/0000950170-23-022236-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2023 ended March 31, 2023"},{"label":"Revenue","value":"$376 thousand"},{"label":"Net income","value":"Net loss of $2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}